Portfolio Lab

Chemed Corp

  • Stock
  • Ticker CHE
  • ISIN US16359R1032
  • NYSE

Health care · Health care services · USA

$548.59 −0.50%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Chemed Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CHEGlobal equities (VT)

$10,000 grew to $38,601. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −42.9% in 03/2026, measured from the peak in 03/2024. The old peak has not been reached again yet.

1-year return
+28.4%
5-year return p.a.
+2.1%
10-year return p.a.
+14.5%
Volatility p.a.
22.0%
Largest decline
−42.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue640647619625639658673691
Gross profit234216185200222216221233
Operating income114956875101858996
EBITDA1301118288117101103111
Net income9072526477666872
Earnings per share6.014.863.574.465.454.845.135.45
Balance sheet
Total assets1,6691,7271,7181,6241,5381,5361,5801,718
Liabilities550545519547559688749857
Equity1,1191,1821,1981,077979848831861
Cash17817425013075174048
Long-term debt–––––91140236
Cash flow
Operating cash flow1653313983134888557
Capital expenditure-13-13-16-17-16-17-16-19
Free cash flow1521912366117716938

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +55.6%, weakest 2025 at −18.9%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$5.45
31 Jul 2026$5.13
28 Apr 2026$4.84
27 Feb 2026$5.45
31 Oct 2025$4.46
31 Jul 2025$3.57
28 Apr 2025$4.86
28 Feb 2025$6.01
1 Nov 2024$5.00
26 Jul 2024$4.65
29 Apr 2024$4.24
29 Feb 2024$5.91

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€6.5bn
Market cap in trading currency
$7.14bn
Enterprise value
$7.33bn
P/E
26.3
P/S
2.68
P/B
8.29
EV/Sales
2.75
EV/EBITDA
16.9
Earnings yield
3.8%
FCF yield
4.1%

Results (last four quarters)

Revenue
$2.66bn
Gross profit
$893m
EBITDA
$433m
Net income
$282m
Earnings per share
$20.87
Revenue per share
$204.46
Revenue growth
+10.6%
Earnings growth
+11.5%

Profitability

Gross margin
33.5%
Operating margin
13.9%
Net margin
10.6%
Return on equity
29.1%
Return on assets
16.4%

Balance sheet and cash flow

Cash
$48.4m
Cash per share
$3.72
Financial debt
$236m
Debt/equity %
27
Current ratio
1.11
Book value per share
$66.19
Operating cash flow
$363m
Free cash flow
$295m

Dividend

Dividend yield
0.46%
Dividend (12 months)
$2.50
Yield (12 months)
0.46%
Payout ratio
12%
Ex-dividend date
17 Aug 2026

Shares and trading

Shares outstanding
13.0m
Volume
134,968
Avg. volume 3 months
150,820
Relative volume
0.9

Price and technicals

Price
$548.59
1 day
−0.5%
52-week high
$552.72
52-week low
$368.59
Distance to 52-week high
−0.7%
Distance to 52-week low
+48.8%
Distance to 50-day line
+5.5%
Distance to 200-day line
+16.6%
RSI (14)
59
Volatility 1M
26.5%

Performance

1 week
+0.1%
1 month
+5.5%
3 months
+1.3%
6 months
+24.9%
YTD
+28.2%
1 year
+27.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CHE performed since 11/2016?

$10,000 grew to $38,601 by 20 Nov 2026, which is +14.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CHE?

Volatility was 22.0% per year, measured on monthly returns. The largest decline from a peak was −42.9%, with the low in 03/2026.

How does CHE compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CHE returned +14.5% at 22.0%. The correlation of monthly returns was 0.32; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Chemed Corp (CHE): Return and risk | Portfolio Lab